Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal IMO-2125 before sentinel node biopsy in thick primary melanoma
NL-OMON26696Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2018
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cutaneous melanoma (CM) comparing IMO-2125 with Placebo (2 arms). Primary endpoint: Tumor-positive sentinel lymph node rate. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
tilsotolimod
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON26696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26696.